Use of copeptin for rapid rule-out of acute myocardial infarction

• Verfasst von: Müller, Christian [VerfasserIn]
• Verfasst von: Giannitsis, Evangelos [VerfasserIn]
• Titel: Use of copeptin for rapid rule-out of acute myocardial infarction
• Verf.angabe: Christian Mueller, Martin Möckel, Evangelos Giannitsis, Kurt Huber, Johannes Mair, Mario Plebani, Kristian Thygesen, Allan S Jaffe, Bertil Lindahl and the ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association
• Jahr: 2018
• Jahr des Originals: 2017
• Umfang: 7 S.
• Fussnoten: Gesehen am 06.05.2019 ; First published: June 8, 2017
• Titel Quelle: Enthalten in: European heart journal - acute cardiovascular care
• Ort Quelle: London [u.a.] : Sage Publ., 2012
• Jahr Quelle: 2018
• Band/Heft Quelle: 7(2018), 6, Seite 570-576
• ISSN Quelle: 2048-8734
• DOI: doi:10.1177/2048872617710791
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1575793938

Abstract

Copeptin is currently understood as a quantitative marker of endogenous stress. It rises rapidly in multiple acute disorders including acute myocardial infarction. As a single variable, it has only modest diagnostic accuracy for acute myocardial infarction. However, the use of copeptin within a dual-marker strategy together with conventional cardiac troponin increases the diagnostic accuracy and particularly the negative predictive value of cardiac troponin alone for acute myocardial infarction. The rapid rule-out of acute myocardial infarction is the only application in acute cardiac care mature enough to merit consideration for routine clinical care. However, the dual-marker approach seems to provide only very small incremental value when used in combination with sensitive or high-sensitivity cardiac troponin assays. This review aims to update and educate regarding the potential and the procedural details, as well as the caveats and challenges of using copeptin in clinical practice.